Risk factors for relapse at the time of ASCT
| Risk factor . | |
|---|---|
| Relapse <12 months after frontline therapy∗ | 27 (41%) |
| Refractory to frontline therapy | 24 (36%) |
| Presence of extranodal involvement at relapse | 23 (34%) |
| Partial response/stable disease pre-ASCT | 22 (33%) |
| ≥2 systemic treatments pre-ASCT | 17 (25%) |
| Presence of B symptoms at relapse | 13 (19%) |
| Number of risk factors | |
| 0 | 4 (6%) |
| ≥1 | 63 (94%) |
| ≥2 | 44 (66%) |
| ≥3 | 14 (21%) |
| Risk factor . | |
|---|---|
| Relapse <12 months after frontline therapy∗ | 27 (41%) |
| Refractory to frontline therapy | 24 (36%) |
| Presence of extranodal involvement at relapse | 23 (34%) |
| Partial response/stable disease pre-ASCT | 22 (33%) |
| ≥2 systemic treatments pre-ASCT | 17 (25%) |
| Presence of B symptoms at relapse | 13 (19%) |
| Number of risk factors | |
| 0 | 4 (6%) |
| ≥1 | 63 (94%) |
| ≥2 | 44 (66%) |
| ≥3 | 14 (21%) |
One patient’s time to relapse was unknown; this patient has 3 other risk factors, and therefore, these data would not change their risk classification.